



ABOUT AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

INNOVATIVE MEDICINES

We have a presence in approximately 100 countries and regions worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Our medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.

TRANSFORMATIVE RESEARCH

Understanding the fundamental biological mechanisms of disease is a defining feature of Amgen's discovery research efforts—and a major contributor to the development of Amgen's deep and broad pipeline of potential new medicines. Amgen's "biology first" approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. With the advances in human genetics, Amgen continues to shed new light on the molecular roots of disease. Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving how we identify and validate human disease targets.

WORLD-CLASS BIOMANUFACTURING

The treatment of millions of seriously ill patients worldwide depends on the safe and reliable production of biologic medicines, which are administered by injection or intravenously. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Significant skill, experience, vigilance and commitment are critical to help ensure the quality of a biologic medicine each time a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.

AMGEN QUICK FACTS

HEADQUARTERS

Thousand Oaks, California

STAFF

Approximately 20,000 worldwide

STOCK LISTING

NASDAQ: AMGN

CHAIRMAN AND CEO

Robert A. Bradway

2018 FINANCIAL HIGHLIGHTS

Total revenue: USD 23.7 billion
Product sales: USD 22.5 billion
Non GAAP R&D expense: USD 3.7 billion

MISSION

To serve patients

VALUES

Be Science-Based

Compete Intensely and Win

Create Value for Patients, Staff and Stockholders

Be Ethical

Trust and Respect Each Other

Ensure Quality

Work in Teams

Collaborate, Communicate and Be Accountable

ABOUT AMGEN AUSTRALIA

Established in 1991, Amgen Australia works to further the company's global efforts to transform the promise of science and biotechnology into therapies that restore health and save lives. Hundreds of thousands of Australians use one of Amgen's 13 products and thousands more have been enrolled in clinical studies that have helped deliver the next generation of innovative treatments. Amgen Australia is proud to support these patients and to contribute to the development of new therapies in partnership with Australia's leading healthcare, academic, research, government and patient organisations.

LOCAL RESEARCH AND DEVELOPMENT

Amgen maintains an extensive clinical trial program and invests significantly in research and development. Amgen's history of clinical trial activity in Australia dates back over 30 years and our reputation for quality and safety continues to make us one of the most trusted destinations in the world for Amgen research. In 2018, this included 665 Australian patients, participating in 49 clinical trials and over 20 investigator-sponsored studies, at more than 75 leading Australian hospitals.

COMMUNITY SUPPORT

At the heart of Amgen Australia's operations is a genuine desire to make a positive impact, not only in the lab, but also in the wider community. This is realised through:

The Amgen Foundation – bringing the excitement of discovery to the scientists of tomorrow through signature programs including The Amgen Biotech Experience and Amgen Scholars. The Amgen Biotech Experience, launched in Australia in 2017 through a partnership with The University of Sydney, provides professional development for teachers as well as teaching materials and research-grade equipment to classrooms to help educate students about the concepts and techniques scientists use to produce medicines. Amgen Scholars, a partnership with The University of Melbourne which launched in 2018, provides hands-on research experience in leading laboratories to undergraduate science students across Australia, New Zealand and Oceania. For further information on Amgen's commitment to STEM and emphasis on inspiring and educating Australia's schoolchildren and undergraduates, visit our website.

Local grants - making a difference by enabling the work of others, particularly in the areas of clinical research and ongoing medical education.

Patient organisations - supporting Rare Cancers Australia, Osteoporosis Australia, Heart Foundation, Kidney Health Australia and others in their efforts to provide information, support and resources that improve prevention, diagnosis, treatment and survival.

Volunteering - providing staff with two days of paid charity leave so they can donate man-hours to important local community groups and projects.

Environmental sustainability - designing practices to measure and reduce environmental impact and build a culture of environmental awareness amongst employees.

REWARDING CAREERS

Amgen Australia offers challenging and rewarding career opportunities for experienced professionals and recent graduates. Amgen maintains a commitment to equal opportunity, gender equity and fosters an inclusive environment of diverse, committed and accomplished people. The company strives to promote a high-performing, team-based environment where employees embrace and leverage each other's talents, nourish innovative thinking, achieve their full potential, and contribute to our success. Visit our website to learn more or join our LiveHire Talent Community (livehire.me) to be considered for employment opportunities.

AMGEN QUICK FACTS

AUSTRALIAN OFFICE LOCATIONS

Head Office (Sydney)

Level 7, 123 Epping Road
North Ryde NSW 2113
T: +61 2 9870 1333
F: +61 2 9870 1344
W: www.amgen.com.au

ABN 31 051 057 428

Melbourne Office

Mezzanine Level
115 Cotham Road
Kew, VIC 3101

T: +61 3 9854 9800
F: +61 3 9818 5123

MEDICAL INFORMATION

T: 1800 803 638 (toll free)

MANAGING DIRECTOR

My Linh Kha

2018 REVENUE

AUD \$341.5 million

STAFF

224 permanent employees

PRODUCTS

Aranesp® (darbepoetin alfa)
BLINCYTO® (blinatumomab)
KYPROLIS® (carfilzomib)
Neulasta® (pegfilgrastim)
NEUPOGEN® (filgrastim)
Nplate® (romiplostim)
Prolia® (denosumab)
Repatha® (evolocumab)
RISTEMPA® (pegfilgrastim)
Sensipar® (cinacalcet)
TEZMOTA® (pegfilgrastim)
Vectibix® (panitumumab)
XGEVA® (denosumab)

For further information about our pipeline and therapies, visit www.amgen.com.au

AFFILIATIONS

Amgen is a proud member of:

- ♦ Medicines Australia
- ♦ AusBiotech
- ♦ American Chamber of Commerce in Australia (AmCham)
- ♦ Australian Packaging Covenant Organisation (APCO)